Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label, Single-Center, Extension Study Evaluating Antibody Persistence Compared to Naive Children and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received a Three-Dose Series of the Novartis Vaccine as Infants in Study V72P9

Trial Profile

A Phase 2, Open-Label, Single-Center, Extension Study Evaluating Antibody Persistence Compared to Naive Children and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received a Three-Dose Series of the Novartis Vaccine as Infants in Study V72P9

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Meningococcal vaccine group B OMV Novartis (Primary) ; Meningococcal vaccine group B
  • Indications Meningococcal group B infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Novartis Vaccines
  • Most Recent Events

    • 28 Apr 2014 New source identified and integrated (United Kingdom Clinical Research Network, 7297)
    • 28 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top